Cox proportional hazards models examining time to VTE events
| Full cohort (N=2299) | Patients with a Khorana risk score (n=472)* | |||
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Cohort (LOT1) (ref: chemo) | ||||
| ICI | 0.74 (0.56 to 0.97) | 0.03 | 0.52 (0.27 to 1.01) | 0.05 |
| ICI+chemotherapy | 1.12 (0.88 to 1.42) | 0.36 | 0.94 (0.55 to 1.61) | 0.81 |
| Age category (ref: 18–55 years) | ||||
| 55–65 years | 0.86 (0.65 to 1.15) | 0.31 | 1.12 (0.55 to 2.27) | 0.76 |
| 65–75 years | 0.87 (0.61 to 1.24) | 0.43 | 1.47 (0.62 to 3.49) | 0.38 |
| ≥75 years | 0.78 (0.50 to 1.22) | 0.28 | 1.60 (0.50 to 5.05) | 0.43 |
| Baseline Khorana risk score | ||||
| 1: low risk for VTE | NA | – | 1.00 | – |
| ≥2: high risk for VTE | NA | 1.17 (0.71 to 1.92) | 0.54 | |
| Cancer pathology (ref: squamous carcinoma) | ||||
| Adenocarcinoma | 1.24 (0.96 to 1.60) | 0.11 | 1.29 (0.75 to 2.23) | 0.36 |
| Other/undetermined/missing | 0.74 (0.36 to 1.53) | 0.42 | 0.45 (0.05 to 4.10) | 0.48 |
| Cancer treatment history during the 12-month baseline period | ||||
| Surgery | 0.88 (0.64 to 1.19) | 0.40 | 0.42 (0.18 to 0.95) | 0.04 |
| Radiation therapy | 1.25 (1.02 to 1.54) | 0.03 | 0.95 (0.57 to 1.57) | 0.84 |
| Baseline BMI category | ||||
| Overweight: 25 to <30 | 1.19 (0.93 to 1.53) | 0.17 | 1.00 (0.57 to 1.78) | 0.99 |
| Class 1 obesity: 30 to <35 | 1.21 (0.89 to 1.64) | 0.22 | 0.73 (0.36 to 1.49) | 0.39 |
| Class 2 obesity: 35 to <40 | 1.26 (0.81 to 1.97) | 0.31 | 0.73 (0.19 to 2.79) | 0.64 |
| Class 3 obesity: ≥40 | 1.77 (0.98 to 3.20) | 0.06 | 2.40 (0.81 to 7.15) | 0.12 |
| Unknown BMI | 1.21 (0.66 to 2.22) | 0.55 | – | – |
| Other baseline comorbidities or procedures | ||||
| Atrial fibrillation | 1.02 (0.69 to 1.52) | 0.92 | 1.26 (0.60 to 2.65) | 0.54 |
| Stroke | 0.87 (0.50 to 1.50) | 0.61 | 1.25 (0.44 to 3.49) | 0.68 |
| Hypertension | 0.94 (0.75 to 1.18) | 0.61 | 1.20 (0.71 to 2.02) | 0.49 |
| Bleeding | 0.97 (0.71 to 1.31) | 0.82 | 1.31 (0.71 to 2.43) | 0.38 |
| Fracture | 1.01 (0.65 to 1.57) | 0.96 | 0.54 (0.14 to 2.10) | 0.37 |
| Transfusions | 1.63 (0.84 to 3.15) | 0.15 | 3.61 (0.68 to 19.21) | 0.13 |
| CVC or PICC | 1.08 (0.87 to 1.34) | 0.48 | 2.13 (1.35 to 3.36) | 0.001 |
| ECOG PS (ref: ECOG PS=0) | ||||
| 1 | 1.04 (0.83 to 1.31) | 0.73 | 1.03 (0.62 to 1.69) | 0.92 |
| 2 and 3 | 1.18 (0.79 to 1.76) | 0.43 | 1.58 (0.64 to 3.89) | 0.32 |
| Unknown | 1.00 (0.58 to 1.71) | 0.99 | 0.32 (0.04 to 2.71) | 0.29 |
| Medication use | ||||
| NSAIDs | 0.91 (0.64 to 1.31) | 0.62 | 0.73 (0.31 to 1.73) | 0.48 |
| Anticoagulants | 0.80 (0.51 to 1.23) | 0.30 | 0.71 (0.29 to 1.75) | 0.45 |
| Antiplatelets | 0.96 (0.65 to 1.42) | 0.83 | 1.03 (0.41 to 2.55) | 0.96 |
| Oral glucocorticoids | 0.90 (0.71 to 1.15) | 0.40 | 0.84 (0.51 to 1.39) | 0.50 |
*For patients with a Khorana risk score, targeted therapy and other combinations were grouped together.
BMI, body mass index; CVC, central venous catheter; ECOG PS, Eastern Cooperative Oncology Group performance status; ICI, immune checkpoint inhibitor; LOT, line of therapy; NSAIDs, non-steroidal anti-inflammatory drugs; PICC, peripherally inserted central catheter; ref, referent; VTE, venous thromboembolism.